Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.
J Cutan Pathol
; 44(5): 462-466, 2017 May.
Article
de En
| MEDLINE
| ID: mdl-28083948
ABSTRACT
Loss of CD26 surface expression on the circulating malignant T-cell is the most widely accepted diagnostic marker in patients with leukemic cutaneous T-cell lymphoma (CTCL). CTCL cases with reemergence of CD7 and/or CD26 surface expression are unusual and of uncertain prognosis. We report the case of an erythrodermic leukemic mycosis fungoides patient who had achieved temporary remission after several months on multimodality immunotherapy and extracorporeal photopheresis, but who relapsed with aggressive disease phenotypically characterized by CD4+ T-cells with high CD26 expression. Polymerase chain reaction studies and high-throughput sequencing analyses from peripheral blood mononuclear cells at presentation and relapse consistently showed an identical clonal T-cell receptor suggesting evolution of her original malignant clone which lacked CD26 expression. Interestingly, quantitative expression of the sialomucin, CD164, mirrored her clinical picture, thus favoring its reliability as a novel biomarker in CTCL.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs cutanées
/
Leucémie à cellules T
/
Lymphocytes T CD4/
/
Marqueurs biologiques tumoraux
/
Régulation de l'expression des gènes codant pour des enzymes
/
Régulation de l'expression des gènes dans la leucémie
/
Mycosis fongoïde
/
Dermatite exfoliatrice
/
Dipeptidyl peptidase 4
/
Protéines tumorales
Type d'étude:
Prognostic_studies
Limites:
Aged
/
Female
/
Humans
Langue:
En
Journal:
J Cutan Pathol
Année:
2017
Type de document:
Article